Aleksandra Stjepanovic
Almirall, S.A.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aleksandra Stjepanovic as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05916365 · Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisAlmirall, S.A. · completed · Atopic Dermatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:26 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.J Allergy Clin Immunol · 2024145 citationsRCR 31.8
- Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.J Diabetes Investig · 20184 citationsRCR 0.2